INDEGENE LIMITED

Indegene Limited held its Q1 FY27 earnings conference call on July 31, 2026, where management discussed the company's performance and industry trends. Management reported that the global pharma industry showed resilient growth, with the top 20 pharma companies achieving 10% to 12% revenue growth year-on-year. Indegene's Q1 revenues reached INR 10,631 million, reflecting a 39.7% year-on-year increase. The active client base grew to 105, with significant contributions from accounts beyond the top 20. Management highlighted strong deal momentum, including several contracts in the $1 million to $5 million range. The company emphasized its unique position as an embedded revenue partner with deep domain expertise and a focus on AI-driven solutions. Financially, EBITDA was reported at INR 1,795 million, with a margin of 16.9%. Management reiterated confidence in achieving margin recovery and continued growth throughout FY27.

Management highlighted strong growth and positive deal momentum in the earnings conference call.